open access

Vol 13, No 5 (2018)
Case Reports
Published online: 2018-09-07
Get Citation

Thrombus in the left atrium after brief interruption of rivaroxaban therapy.

Małgorzata Ewa Buksińska-Lisik, Hanna Mularczyk, Artur Mamcarz
DOI: 10.5603/FC.a2018.0086
·
Folia Cardiologica 2018;13(5):453-455.

open access

Vol 13, No 5 (2018)
Case Reports
Published online: 2018-09-07

Abstract

Planning an invasive procedure with a high risk of bleeding is the most common reason for the temporary interruptions of anticoagulant therapy in patients with atrial fibrillation. The bridging therapy is strongly recommended only in patients with mechanical heart valves. The case report presents a 75-year-old patient with ischemic stroke and left atrial thrombus occurred after a short treatment interruption with rivaroxaban without bridging therapy in a patient with “nonvalvular” atrial fibrillation.

Abstract

Planning an invasive procedure with a high risk of bleeding is the most common reason for the temporary interruptions of anticoagulant therapy in patients with atrial fibrillation. The bridging therapy is strongly recommended only in patients with mechanical heart valves. The case report presents a 75-year-old patient with ischemic stroke and left atrial thrombus occurred after a short treatment interruption with rivaroxaban without bridging therapy in a patient with “nonvalvular” atrial fibrillation.

Get Citation

Keywords

left atrial thrombus; atrial fibrillation; ischemic stroke; rivaroxaban

About this article
Title

Thrombus in the left atrium after brief interruption of rivaroxaban therapy.

Journal

Folia Cardiologica

Issue

Vol 13, No 5 (2018)

Pages

453-455

Published online

2018-09-07

DOI

10.5603/FC.a2018.0086

Bibliographic record

Folia Cardiologica 2018;13(5):453-455.

Keywords

left atrial thrombus
atrial fibrillation
ischemic stroke
rivaroxaban

Authors

Małgorzata Ewa Buksińska-Lisik
Hanna Mularczyk
Artur Mamcarz

References (7)
  1. January CT, Wann LS, Alpert JS, et al. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Heart Rhythm Society. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report. J Am Coll Cardiol. 2014; 64(21): e1–76.
  2. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  3. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013; 61(6): 651–658.
  4. Sherwood MW, Douketis JD, Patel MR, et al. ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014; 129(18): 1850–1859.
  5. Douketis JD, Spyropoulos AC, Kaatz S, et al. BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373(9): 823–833.
  6. Watanabe A, Yamashita N, Yamashita T. Blood stasis secondary to heart failure forms warfarin-resistant left atrial thrombus. Int Heart J. 2014; 55(6): 506–511.
  7. Kim MN, Kim SA, Choi Ji, et al. Improvement of predictive value for thromboembolic risk by incorporating left atrial functional parameters in the CHADS2 and CHA2DS2-VASc scores. Int Heart J. 2015; 56(3): 286–292.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl